Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials.

Leroux-Roels I, Devaster JM, Leroux-Roels G, Verlant V, Henckaerts I, Moris P, Hermand P, Van Belle P, Poolman JT, Vandepapelière P, Horsmans Y.

Vaccine. 2015 Jan 15;33(4):577-84. doi: 10.1016/j.vaccine.2013.10.052. Epub 2013 Oct 29.

2.

Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera.

Rose CE, Romero-Steiner S, Burton RL, Carlone GM, Goldblatt D, Nahm MH, Ashton L, Haston M, Ekström N, Haikala R, Käyhty H, Henckaerts I, Durant N, Poolman JT, Fernsten P, Yu X, Hu BT, Jansen KU, Blake M, Simonetti ER, Hermans PW, Plikaytis BD.

Clin Vaccine Immunol. 2011 Jan;18(1):135-42. doi: 10.1128/CVI.00370-10. Epub 2010 Nov 17.

3.

Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines.

Poolman JT, Frasch CE, Käyhty H, Lestrate P, Madhi SA, Henckaerts I.

Clin Vaccine Immunol. 2010 Jan;17(1):134-42. doi: 10.1128/CVI.00289-09. Epub 2009 Nov 4.

4.

Pneumococcal carriage and acute otitis media induce serum antibodies to pneumococcal surface proteins CbpA and PhtD in children.

Simell B, Ahokas P, Lahdenkari M, Poolman J, Henckaerts I, Kilpi TM, Käyhty H.

Vaccine. 2009 Jul 23;27(34):4615-21. doi: 10.1016/j.vaccine.2009.05.071. Epub 2009 Jun 12.

PMID:
19524618
5.

Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics.

Poolman J, Kriz P, Feron C, Di-Paolo E, Henckaerts I, Miseur A, Wauters D, Prymula R, Schuerman L.

Vaccine. 2009 May 21;27(24):3213-22. doi: 10.1016/j.vaccine.2009.03.017. Epub 2009 Mar 26.

PMID:
19446194
6.

Pneumococcal Haemophilus influenzae protein D conjugate vaccine induces antibodies that inhibit glycerophosphodiester phosphodiesterase activity of protein D.

Toropainen M, Raitolehto A, Henckaerts I, Wauters D, Poolman J, Lestrate P, Käyhty H.

Infect Immun. 2008 Oct;76(10):4546-53. doi: 10.1128/IAI.00418-08. Epub 2008 Jul 21.

7.
8.

Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly.

Ortqvist A, Henckaerts I, Hedlund J, Poolman J.

Vaccine. 2007 Mar 22;25(13):2445-50. Epub 2006 Sep 20.

PMID:
17052816
9.

Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children.

Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J.

Vaccine. 2007 Mar 22;25(13):2518-27. Epub 2006 Sep 20.

PMID:
17034907
11.

Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants.

Nurkka A, Joensuu J, Henckaerts I, Peeters P, Poolman J, Kilpi T, Käyhty H.

Pediatr Infect Dis J. 2004 Nov;23(11):1008-14.

PMID:
15545855

Supplemental Content

Loading ...
Support Center